Lundbeckfond Invest A/S 3
3 · IO Biotech, Inc. · Filed Nov 4, 2021
Insider Transaction Report
Form 3
IO Biotech, Inc.IOBT
Lundbeckfond Invest A/S
Director10% Owner
Holdings
Series B Preferred Stock
[F1]→ Common Stock (2,014,161 underlying)Series C Preferred Stock
[F2]→ Common Stock (1,892,434 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series B Preferred Stock have no expiration date.
- [F2]Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series C Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series C Preferred Stock have no expiration date.
Signature
Lundbeckfond Invest A/S, by: /s/ Brian Burkavage, Attorney-in-Fact for Christian Elling, Managing Partner, and Lene Skole, Chief Executive Officer|2021-11-04